43 reports of this reaction
4.8% of all BUTENAFINE HYDROCHLORIDE reports
#3 most reported adverse reaction
PRODUCT USE ISSUE is the #3 most commonly reported adverse reaction for BUTENAFINE HYDROCHLORIDE, manufactured by Bayer Healthcare LLC.. There are 43 FDA adverse event reports linking BUTENAFINE HYDROCHLORIDE to PRODUCT USE ISSUE. This represents approximately 4.8% of all 901 adverse event reports for this drug.
Patients taking BUTENAFINE HYDROCHLORIDE who experience product use issue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT USE ISSUE is moderately reported among BUTENAFINE HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to product use issue, the following adverse reactions have been reported for BUTENAFINE HYDROCHLORIDE:
The following drugs have also been linked to product use issue in FDA adverse event reports:
PRODUCT USE ISSUE has been reported as an adverse event in 43 FDA reports for BUTENAFINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT USE ISSUE accounts for approximately 4.8% of all adverse event reports for BUTENAFINE HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience product use issue while taking BUTENAFINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.